Overview

Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.

Status:
Completed
Trial end date:
2004-07-01
Target enrollment:
Participant gender:
Summary
The objectives of this study were to evaluate the efficacy and safety of drospirenone 3 mg/ethinyl estradiol 0.02 mg (DRSP/EE) in comparison with placebo in female subjects with moderate acne vulgaris during 6 treatment cycles.
Phase:
Phase 3
Details
Lead Sponsor:
Bayer